Managing reactivation of multiple sclerosis during treatment with natalizumab.

ABSTRACT:

Background

Following natalizumab failure, it is unknown whether switching to alternative high-efficacy therapies offers superior effectiveness over continuing natalizumab.

Objective

To compare different treatment strategies following natalizumab failure.

Methods

Patients suffering a relapse during natalizumab treatment with adequate follow-up were identified from the MSBase registry. Following natalizumab failure, natalizumab continuation was compared to switching to anti-CD20 therapies/alemtuzumab/lower-efficacy therapies and treatment discontinuation. The primary outcome was the risk of further relapses. Secondary outcomes included risk of subsequent magnetic resonance imaging (MRI) activity, confirmed disability worsening and disease-activity-free survival. Multiva

SUBMITTER: Lizak N 

PROVIDER: S-EPMC12756529 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature